Laboratoire Francais Du Fractionnement Et Des Biotechnologies
SpainAll drugs from this manufacturer
-
It is used in adults and adolescents (from 12 years of age and older) with hemophilia A or B who have developed inhibitors (antibodies). It is used to treat bleeding episodes and for the management of bleeding during surgery.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eptacog beta activated 1 mg -
It is used in adults and adolescents (12 years or older) with hemophilia A or B who have developed inhibitors to treat bleeding episodes or for the management of bleeding during surgery.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eptacog beta activated 2 mg -
It is used in adults and adolescents (from 12 years of age and older) with hemophilia A or B who have developed inhibitors to treat bleeding episodes or to manage bleeding during surgery.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eptacog beta activated 5 mg -
It is used to treat bleeding in people with congenital fibrinogen deficiency, a hereditary disease in which the body has little or no amount of this protein, causing the blood to take too long to clot.
Dosage form: powder and solvent for solution for injection and for infusion
Active substance Dosage human fibrinogen 1,50 g -
It is used to treat patients who do not have sufficient antibodies (whether due to a congenital or acquired deficiency) and to treat certain inflammatory disorders, such as primary immune thrombocytopenia, Guillain-Barré syndrome, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
Dosage form: solution for infusion
Active substance Dosage human immunoglobulin g 100 mg